Zobrazeno 1 - 8
of 8
pro vyhledávání: '"John Abran"'
Autor:
Daniel J. Canter, MD, Caroline Branch, MSN, NP-C, Jason Shelnutt, MBA, Aimee J. Foreman, MA, Amy M. Lehman, MAS, Varun Sama, MS, David K. Edwards, V, PhD, John Abran, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 4, Pp 101193- (2023)
Purpose: The objective of this study was to assess the association between the Oncotype DX Genomic Prostate Score (GPS) assay and long-term outcomes in men with localized prostate cancer (PCa) after radiation therapy (RT). We hypothesized that the GP
Externí odkaz:
https://doaj.org/article/cd2d5abc7b4043fd87fe1694031a6e4b
Autor:
Brian T Helfand, Michael Paterakos, Chi-Hsiung Wang, Pooja Talaty, John Abran, John Bennett, David W Hall, Amy Lehman, Tamer Aboushwareb
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0273782 (2022)
The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus defini
Externí odkaz:
https://doaj.org/article/415a89c1d4b547ff9b6c7d46443f359f
Autor:
Daniel Canter, Caroline Branch, Joao Zambon, Jack Groskopf, Aimee Foreman, Amy Lehman, Varun Sama, David Edwards, John Abran
Publikováno v:
Journal of Urology. 209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::657b2717bc579885561cb03d396f6e9e
https://doi.org/10.1097/ju.0000000000003237.03
https://doi.org/10.1097/ju.0000000000003237.03
Autor:
Cristina Magi-Galluzzi, Michael Brooks, Tamer Aboushwareb, Lewis Thomas, Eric A. Klein, Ruixiao Lu, Jianbo Li, Michael Crager, John Abran
Publikováno v:
JCO Precision Oncology
PURPOSE To assess the association between the Oncotype DX Genomic Prostate Score (GPS) result and long-term oncological outcomes following radical prostatectomy (RP). METHODS We evaluated the association of the GPS result assayed from the index lesio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27982ad14d930f49e18ce9db841f52c
https://doi.org/10.1200/po.20.00325
https://doi.org/10.1200/po.20.00325
Autor:
Frederick L. Baehner, Andrea Blacklock, John Abran, Vivian Tan, Helen Bailey, Rebekah Young, Debbie M Jakubowski, Carolyn Mies, Anna Lau, Nancy Ciau
Publikováno v:
Journal of Surgical Oncology
Background and Objective Recent COVID‐19 pandemic guidelines recommend genomic assessment of core biopsies to help guide treatment decisions in estrogen receptor (ER)‐positive early‐stage breast cancer. Herein we characterize biopsy and excisio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3284b559fffdabfc59106ee14c2bcb87
https://doi.org/10.1002/jso.26050
https://doi.org/10.1002/jso.26050
Autor:
Brian T. Helfand, Michael Paterakos, Chi-Hsiung Wang, Pooja Talaty, John Abran, John Bennett, David W. Hall, Amy Lehman, Tamer Aboushwareb
Publikováno v:
PloS one. 17(9)
The validated 17-gene Oncotype DX Genomic Prostate Score® (GPS™) assay risk-stratifies prostate-cancer patients with localized disease. The assay has primarily been utilized in lower risk patients deciding between active surveillance versus defini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aba5446253eff7934dd96424e3cc056
https://pubmed.ncbi.nlm.nih.gov/36048818
https://pubmed.ncbi.nlm.nih.gov/36048818
Autor:
L.J. Thomas, Ruixiao Lu, Tamer Aboushwareb, Eric A. Klein, Cristina Magi-Galluzzi, Jianbo Li, Frederick L. Baehner, John Abran, Michael Crager, Michael Brooks
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 40:104.e1-104.e7
PURPOSE To assess the association of adverse pathology (AP), defined as high-grade (≥ Gleason Grade Group 3) and/or non-organ confined disease, with long-term oncologic outcomes after radical prostatectomy (RP). MATERIALS AND METHODS Using a strati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad1f2fbfac9cc1cbfa4f45845b8124e
https://doi.org/10.1016/j.urolonc.2021.10.005
https://doi.org/10.1016/j.urolonc.2021.10.005
Autor:
Cristina Magi-Galluzi, Tamer Aboushwareb, Michael Crager, Eric A. Klein, Ruixiao Lu, Lewis Thomas, Michael Brooks, Jianbo Li, John Abran
Publikováno v:
Journal of Clinical Oncology. 39:219-219
219 Background: Adverse pathology (AP) at radical prostatectomy (RP) is often used as a proxy for long-term prostate cancer outcomes. The goal of this study was to assess the association of AP at RP, defined as high-grade (> Grade Group 3) and/or non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e2ff1316f158da387f78324aa1efa77
https://doi.org/10.1200/jco.2021.39.6_suppl.219
https://doi.org/10.1200/jco.2021.39.6_suppl.219